Effect of Lactoferrin in Pneumonia Treatment

Not Applicable

• Conditions: Pneumonia
• Interventions: Drug: Pneumonia treatment; Drug: Lactoferrin

• Registration Number: NCT05431023
• Lead Sponsor: Assiut University

Brief Summary

Pneumonia is defind as the inflammation of lung tissue caused by an infectious agent that results in acute respiratory signs and symptoms. Community acquired pneumonia (CAP) is a major cause of morbidity and increased health care costs. In developing nations, pneumonia remains a significant cause of mortality in children.

Pneumonia occurs in 30 to 45 of every 1,000 children under 5 years of age; it is less common in 5- to 9-year olds (16 to 22/1,000) and in older children (7 to 16/1,000).

Streptococcus pneumoniae is the primary bacterial cause of pneumonia in infants and children. Viral etiologies become less prevalent and mycoplasmal and chlamydial infections become more prevalent with increasing age

Detailed Description

Lactoferrin (LF) is iron-binding glycoprotein of the transferrin family that is expressed and secreted by glandular cells and is found in most body fluids . It appears at especially high concentrations in mammalian milk and was first identified in bovine milk , and was subsequently isolated from human milk.

LFs bacteriostatic function is due to its ability to take up the Fe3+ ion, limiting use of this nutrient by bacteria at the infection site and inhibiting the growth of these microorganisms as well as the expression of their virulence factors .

Study Timeline

• Study First Submitted: 2022-03-12
• Status Verified: 2022-06
• Study First Submitted QC: 2022-06-18
• Last Update Submitted: 2022-06-18
• Study First Posted: 2022-06-24
• Last Update Posted: 2022-06-24
• Study Start: 2022-08-01
• Primary Completion: 2023-08-01
• Study Completion: 2024-08-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

• Pneumonia patients
• from the age of one month to the age of 18 years .

Read More

Exclusion Criteria

Neonates and any children with :

• immune deficiency
• congenital heart disease
• neuromascular disorder
• genetic syndromes

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Patients with pneumonia who receive only treatment for pneumonia	Pneumonia treatment	They receive only treatment for pneumonia
pneumonia patients receive treatment for pneumonia and lactoferrin	Pneumonia treatment	They receive treatment for pneumonia and lactoferrin
pneumonia patients receive treatment for pneumonia and lactoferrin	Lactoferrin	They receive treatment for pneumonia and lactoferrin

Primary Outcome Measures

Name	Time	Method
Survival rate.	Up to 8 weeks	Comparing the influence of the intervention on the Survival rate.

Secondary Outcome Measures

Name	Time	Method
Mean change in the disease severity (clinical assessment)	Up to 4 weeks	Recording the changes from severe to moderate or mild and the time taken